美国非处方助听器的潜在临床与经济结局
该成本效果分析使用经验证听力损失决策模型,模拟美国40岁及以上成人在初级保健诊所的终生结局。与提供传统助听器相比,提供非处方助听器在效用获益为传统助听器55%及以上时具有成本效果(ICER<$100 000/QALY),概率不确定性分析中53%的模拟具有成本效果。
要点
- 非处方助听器效用获益为0.06或以上(传统助听器效果的55%)时,具有成本效果(ICER<$100 000/QALY)。
- 非处方助听器提供与终生贴现成本增加$70至$200相关,同时因助听器使用率增加而伴非处方设备成本$200至$1000/对。
- 概率不确定性分析中,非处方助听器提供在53%的模拟中具有成本效果。
核心结论
- 在该成本效果分析中,提供非处方助听器与听力干预使用率增加相关,并且只要非处方助听器对患者生活质量的益处大于传统助听器的55%,在一系列价格范围内具有成本效果。
研究设计与样本
- 成本效果分析,使用先前验证的听力损失决策模型模拟美国40岁及以上成人在美国初级保健诊所的终生结局。
主要发现
- 传统助听器提供产生18.162 QALYs,非处方助听器产生18.162至18.186 QALYs,随非处方助听器效用获益(传统助听器的45%-100%)变化。
- 提供非处方助听器与终生贴现成本增加$70至$200相关,同时伴非处方设备成本$200至$1000/对(传统助听器成本的5%-38%),原因为助听器使用率增加。
- 若非处方助听器效用获益为0.06或以上(传统助听器效果的55%),提供非处方助听器被认为具有成本效果(ICER<$100 000/QALY)。
- 在概率不确定性分析中,提供非处方助听器在53%的模拟中具有成本效果。
关键数值与推荐
- 传统助听器获取概率为0.5%-8.1%/年,固定获取成本为$3690,效用获益为0.11额外utils/年。
- 非处方助听器获取概率为1%-16%/年,基于首次听力损失诊断时间估计。
- 基础案例中,非处方助听器效用获益范围为0.05至0.11额外utils/年(传统助听器的45%-100%),成本为$200至$1400(传统助听器的5%-38%)。
- 成本效果阈值:ICER<$100 000/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Over-the-counter (OTC) hearing aids are now available in the US; however, their clinical and economic outcomes are unknown. OBJECTIVE: To project the clinical and economic outcomes of traditional hearing aid provision compared with OTC hearing aid provision. DESIGN, SETTING, AND PARTICIPANTS: This cost-effectiveness analysis used a previously validated decision model of hearing loss (HL) to simulate US adults aged 40 years and older across their lifetime in US primary care offices who experienced yearly probabilities of acquiring HL (0.1%-10.4%), worsening of their HL, and traditional hearing aid uptake (0.5%-8.1%/y at a fixed uptake cost of $3690) and utility benefits (0.11 additional utils/y). For OTC hearing aid provision, persons with perceived mild to moderate HL experienced increased OTC hearing aid uptake (1%-16%/y) based on estimates of time to first HL diagnosis. In the base case, OTC hearing aid utility benefits ranged from 0.05 to 0.11 additional utils/y (45%-100% of traditional hearing aids), and costs were $200 to $1400 (5%-38% of traditional hearing aids). Distributions were assigned to parameters to conduct probabilistic uncertainty analysis. INTERVENTION: Provision of OTC hearing aids, at increased uptake rates, across a range of effectiveness and costs. MAIN OUTCOMES AND MEASURES: Lifetime undiscounted and discounted (3%/y) costs and quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). RESULTS: Traditional hearing aid provision resulted in 18.162 QALYs, compared with 18.162 to 18.186 for OTC hearing aids varying with OTC hearing aid utility benefit (45%-100% that of traditional hearing aids). Provision of OTC hearing aids was associated with greater lifetime discounted costs by $70 to $200 along with OTC device cost ($200-$1000/pair; 5%-38% traditional hearing aid cost) due to increased hearing aid uptake. Provision of OTC hearing aids was considered cost-effective (ICER<$100 000/QALY) if the OTC utility benefit was 0.06 or greater (55% of the traditional hearing aid effectiveness). In probabilistic uncertainty analysis, OTC hearing aid provision was cost-effective in 53% of simulations. CONCLUSIONS AND RELEVANCE: In this cost-effectiveness analysis, provision of OTC hearing aids was associated with greater uptake of hearing intervention and was cost-effective over a range of prices so long as OTC hearing aids were greater than 55% as beneficial to patient quality of life as traditional hearing aids.
引用
- Borre ED, Johri M, Dubno JR, et al. Potential Clinical and Economic Outcomes of Over-the-Counter Hearing Aids in the US. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 37200042. doi:10.1001/jamaoto.2023.0949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。